Marché mondial de la maladie de Cushing – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché de la maladie de Cushing devrait connaître une croissance rapide au cours de la période de prévision. Le syndrome de Cushing est un groupe de symptômes provoqués par un taux élevé d'hormones cortisol. Le syndrome, également connu sous le nom d'hypercortisolisme, est fréquemment induit par les effets indésirables des corticostéroïdes. L'inflammation et les maladies auto-immunes sont généralement traitées par des corticostéroïdes. Le syndrome de Cushing iatrogène et le syndrome de Cushing endogène sont les deux types de syndrome de Cushing. La prise de poids, les dépôts de tissu adipeux autour de l'abdomen et du dos, les vergetures violettes, la peau plus fine qui se meurtrit facilement, l'acné et d'autres symptômes sont courants.

Data Bridge Market Research analyse que le marché de la maladie de Cushing était évalué à 333,80 millions USD en 2021 et devrait atteindre 686,89 millions USD d'ici 2029, enregistrant un TCAC de 9,44 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

L'hypertension artérielle, les vergetures rougeâtres, l'obésité abdominale, le visage rond et rouge, la faiblesse des muscles, la faiblesse des os, une masse graisseuse entre les épaules et une peau délicate qui guérit lentement sont tous des symptômes et des indicateurs du syndrome de Cushing. Le syndrome de Cushing est causé par deux facteurs principaux : la prise excessive de médicaments de type cortisol comme la prednisone et les tumeurs formées par la surproduction de cortisol par les glandes surrénales. D'autres tumeurs, telles que celles liées à des maladies héréditaires, notamment la néoplasie endocrinienne multiple de type 1 et le complexe de Carney, peuvent potentiellement être responsables de cette affection. Dans la plupart des cas, une combinaison de chirurgie, de radiothérapie et de chimiothérapie peut être utilisée pour traiter et guérir la maladie.

Portée du rapport et segmentation du marché

Dynamique du marché de la maladie de Cushing

Conducteurs

• Prévalence croissante de la maladie de Cushing

La prévalence croissante de la maladie de Cushing devrait favoriser la croissance du marché. Selon l'Orphanet Journal of Rare Disease, le syndrome de Cushing devrait avoir une incidence annuelle de 1 à 3 cas par million d'habitants, mais sa fréquence était proche de 40 cas par million d'habitants en 2012. Le syndrome de Cushing, également connu sous le nom d'hypercortisolisme, est une maladie hormonale caractérisée par une exposition continue des tissus corporels à des quantités excessives de l'hormone cortisol. Le syndrome de Cushing touche les adultes âgés de 20 à 50 ans.

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important qui influence le taux de croissance du marché de la maladie de Cushing est l'augmentation des dépenses de santé qui contribue à améliorer son infrastructure. En outre, diverses organisations gouvernementales visent à améliorer l'infrastructure des soins de santé en augmentant le financement, ce qui influencera davantage la dynamique du marché.

• Nombre croissant de personnes âgées

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Cushing's disease, further estimated to enhance the market's growth rate. Cushing's disease is uncommon, however, it is at risk of developing in obese patients with type 2 diabetes, high blood pressure, and poorly regulated blood glucose.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Cushing's disease market. Additionally, changing lifestyles of people and rising level of disposable income will result in the expansion of Cushing's disease market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Cushing's disease market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for Cushing's disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Cushing's disease market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This Cushing's disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Cushing's disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cushing's disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cushing's Disease Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Cushing's disease market was hampered by the supply chain slowness.

Recent Development

• In March 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Isturisa (osilodrostat) oral tablets for adults suffering from Cushing's disease who cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Isturisa is the first FDA-approved medicine to directly target cortisol overproduction by inhibiting the enzyme 11-beta-hydroxylase and stopping cortisol manufacture.

Global Cushing's Disease Market Scope

The Cushing's disease market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Surgery
• Radiation Therapy
• Drugs
  • Ketoconazole
  • Mitotane
  • Aminoglutethimide
  • Metyrapone
  • Mifepristone
  • Etomidate
  • Pasireotide
  • Others

Diagnosis

• Petrosal Sinus Sampling
• Saliva Test
• Urine and Blood Tests
• Imaging Tests
  • Computerized tomography (CT) scans
  • Magnetic resonance imaging (MRI)
  • Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cushing's Disease Market Regional Analysis/Insights

The Cushing's disease market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Cushing's disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Cushing's disease market because of the rising number of research activities and the growing prevalence of obesity population in this region. Additionally, rising healthcare expenditure and favorable government policies will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to the increasing level of disposable income in this region. Also, the development of healthcare infrastructure and rising awareness about the diseases will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cushing's Disease Market Share Analysis

The Cushing's disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Cushing's disease market.

Some of the major players operating in the Cushing's disease market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG (Allemagne)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Société Bristol-Myers Squibb (États-Unis)
• Eli Lilly and Company (États-Unis)
• Strides Pharma Science Limited (Inde)
• Cipla Inc. (États-Unis)
• LEO Pharma A/S (Danemark)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Hikma Pharmaceuticals PLC (Royaume-Uni)

SKU-54306